Vesicoureteral Reflux, Treatment with Periureteral Bulking Agents
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity, coverage criteria, and coding guidance for use of periureteral (endoscopic) bulking agents to treat pediatric vesicoureteral reflux (VUR) for Blue Cross Blue Shield of North Carolina providers and members.
No material clinical or coverage changes in this revision.
Coverage Criteria
Medically necessary coverage
Covered when ALL of the following are met
Per policy: periureteral bulking agents may be considered medically necessary for VUR grades II–IV when medical therapy has failed and open surgical intervention is otherwise indicated. Evidence from RCTs and systematic reviews supports similar reflux resolution and comparable or lower morbidity versus ureteral reimplantation in this population.
First-line treatment — Not established/Insufficient evidence for first-line use
Not established/Insufficient evidence for first-line use
Additional larger studies are needed to determine efficacy as first-line treatment.
The policy specifies contraindications and relevant clinical context for periureteral bulking agents. Use is contraindicated in patients with non-functioning kidney(s), Hutch diverticulum (Hutch diverticuli), ureterocele, active voiding dysfunction, and ongoing urinary tract infection. Duplicated ureters were formerly considered a contraindication to Deflux® but were changed to a precaution in 2007. Certain agents (for example, polytetrafluoroethylene paste/Teflon) have safety concerns such as particle migration and are not FDA approved for VUR; other previously used agents have been discontinued because of immune reaction or other safety concerns.
This portion of the document fragment does not list additional explicit exclusions for periureteral bulking agent treatment beyond those provided in the contraindications and description sections.
Periureteral bulking agents are considered investigational/insufficient as first‑line therapy for patients with VUR who have not failed medical therapy or who may be ineligible for surgery. Randomized controlled trials comparing endoscopic bulking injections to antibiotic prophylaxis or surveillance had relatively small sample sizes and produced mixed findings; additional larger studies are needed before the therapy can be recommended as first‑line treatment. The policy therefore limits medical necessity to patients with VUR grades II–IV who have failed medical therapy and for whom open surgical intervention would otherwise be indicated, and considers other clinical scenarios investigational.
No explicit statements labeled ‘not medically necessary’ are present in this fragment beyond the policy’s characterization of non‑listed clinical situations as investigational; benefits and eligibility remain subject to the member’s contract and prior authorization determinations where applicable.
Coding and Billing Codes
| L8604 | Implantable bulking agent, dextranomer/hyaluronic acid copolymer (Deflux), per implant |
Provider Actions, Prior Authorization & Documentation
Prior authorization may be required; applicable codes 52327, L8604
Prior authorization or a medical necessity determination may be required for periureteral bulking agent procedures. Applicable service codes called out in the policy are 52327 (endoscopic injection of implant material into ureteral orifice(s)) and L8604 (implantable bulking agent, dextranomer/hyaluronic acid copolymer - Deflux).
No specific prior-authorization steps listed
The policy text does not specify additional or explicit prior authorization policy steps or criteria beyond stating that a medical necessity determination may be required.
Document failed medical therapy before treatment
Periureteral bulking agent treatment is covered only after medical therapy has failed and when open surgical intervention would otherwise be indicated; confirm documentation that medical therapy was attempted and failed before submitting for consideration.
- Medical therapy must have failed prior to consideration of periureteral bulking agents
- Patient should be otherwise eligible for open surgical intervention
No specific step therapy requirements specified
The document does not specify any formal step therapy program or stepwise medication requirements beyond the requirement that medical therapy has failed; no additional step therapy rules are provided.
Provide full medical records; letters alone may be insufficient
BCBSNC may request medical records to determine medical necessity; letters of support or explanation can be useful but are not sufficient unless they include all specific information needed for the determination.
- Provide complete medical records when requested; letters alone may be insufficient
- Include documentation of VUR grade, prior medical therapy, and surgical eligibility
Policy is informational; verify benefits/eligibility separately
This medical policy is informational and is not an authorization or guarantee of benefits; benefits and eligibility are determined by the group contract and subscriber certificate in effect at the time of service.
Failure to supply requested records may trigger denial
BCBSNC may request medical records for medical necessity review; failure to provide required documentation may result in denial of coverage.
- Ensure records include documentation supporting diagnosis, VUR grade, prior therapy, and surgical candidacy
Investigational for indications outside VUR grades II–IV after failed therapy
Use of periureteral bulking agents for indications other than VUR grades II–IV after failed medical therapy when surgery is indicated is considered investigational and may be denied.
- Treatment outside the specified VUR grades (II–IV) or without prior failed medical therapy is investigational
No specific denial triggers provided in this policy fragment
The document fragment does not list specific denial triggers; reviewers rely on requested documentation and coverage criteria to determine medical necessity.
Background
Vesicoureteral reflux (VUR) is the retrograde flow of urine from the bladder toward the kidney and is most often diagnosed in children. VUR increases the risk of urinary tract infections and renal scarring, which can lead to long-term complications including renal insufficiency and hypertension. Diagnosis is typically made by voiding cystourethrography using the International Reflux Grading system (grades I–V), with lower grades more likely to resolve spontaneously. Management options range from observation and bladder training with antibiotic prophylaxis to definitive surgical repair; endoscopic periureteral bulking injection is an additional, less invasive option that is considered in selected pediatric patients.
Definitions and Procedures
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.